Abstract | BACKGROUND: PATIENTS AND METHODS: We reviewed the records of all patients who received VEGFR-TKIs concomitantly with BRIs. Patients, who were treated with BRIs without VEGFR-TKI, served as a control group. Endpoints of the study were total MRONJ-incidence, MRONJ-incidence during the first and second year of exposure, and time-to-ONJ-incidence. RESULTS: Ninety patients were treated concomitantly with BRIs and VEGFR-TKIs with a median BRI-exposure of 5.0 months. Total MRONJ-incidence was 11.1%. During the first year of BRI-exposure (with a median concomitant exposure of 4.0 months), 6 out of 90 patients (6.7%) developed a MRONJ, compared to 1.1% in the control group (odds ratio 5.9; 95%CI 2.0-18.0; p = 0.0035). In Kaplan-Meier estimates, time-to-ONJ-incidence was significantly shorter in patients treated with BRIs and VEGFR-TKIs compared to BRIs alone (hazard ratio 9.5; 95%CI 3.1-29.6; p < 0.0001). MRONJs occurred earlier in patients treated concomitantly compared to patients treated with BRIs only (after a median exposure of 4.5 and 25.0 months, respectively; p = 0.0033). CONCLUSION: With a global MRONJ-incidence of 11%, patients receiving concomitant treatment with VEGFR-TKIs and BRIs have a five to ten times higher risk for development of MRONJ compared to patients treated with BRIs alone.
|
Authors | T van Cann, T Loyson, A Verbiest, P M Clement, O Bechter, L Willems, I Spriet, R Coropciuc, C Politis, R O Vandeweyer, J Schoenaers, P R Debruyne, H Dumez, P Berteloot, P Neven, K Nackaerts, F J S H Woei-A-Jin, K Punie, H Wildiers, B Beuselinck |
Journal | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
(Support Care Cancer)
Vol. 26
Issue 3
Pg. 869-878
(Mar 2018)
ISSN: 1433-7339 [Electronic] Germany |
PMID | 28963584
(Publication Type: Journal Article)
|
Chemical References |
- Bone Density Conservation Agents
- Protein Kinase Inhibitors
- Vascular Endothelial Growth Factor A
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Bisphosphonate-Associated Osteonecrosis of the Jaw
(drug therapy, pathology)
- Bone Density Conservation Agents
(adverse effects, pharmacology)
- Female
- Humans
- Incidence
- Male
- Middle Aged
- Protein Kinase Inhibitors
(adverse effects, pharmacology)
- Vascular Endothelial Growth Factor A
(adverse effects, pharmacology)
- Young Adult
|